The culture of hematopoietic stem and progenitor cells (HSPCs) is important to assay the quality and functional properties of HSPCs e.g., during the implementation of transplantation or other approaches to treat hematological disorders, such as leukemia. Examples of HSPC culture assays include colony-forming unit (CFU) assays in semi-solid methylcellulose-based media, such as MethoCult™, to identify and quantify HSPCs, and expansion cultures in liquid media, such as StemSpan™, to increase HSPC numbers or generate large numbers of mature blood cells. These culture methods can also used to evaluate the efficacy and toxicity of new drug candidates on hematopoiesis in vitro and to generate target cells for reprogramming to generate induced pluripotent stem cells.
In this Ask the Expert Session, we will discuss challenges and techniques for the culture of HSPCs, including the use of serum-free, defined media and supplements that have been developed by STEMCELL Technologies for HSPC culture applications.
This session is sponsored by STEMCELL Technologies and hosted by Dr. Bert Wognum. Dr. Wognum is the Principal Scientistfor Hematopoietic & Immunopoietic Products in R&D at STEMCELL Technologies, and currently leads the development of new media and supplements for the expansion, differentiation and detection of HSPCs in culture.
Dr. Wognum obtained his PhD at the University of Amsterdam in the Netherlands and worked as a postdoctoral fellow at the Terry Fox Laboratory in Vancouver, Canada, and the Department of Hematology at Erasmus University in Rotterdam, the Netherlands. He studied the role of hematopoietic growth factors and their receptors in normal hematopoiesis and leukemia and contributed to preclinical studies aimed at improving hematopoietic recovery after cytoreductive therapy and transplantation.
Questions about the culture of HSPCs?
During this Ask the Expert session, Dr. Bert Wognum will be answering your questions about StemSpan™ media and supplements for serum-free HSPC expansion, along with highlighting recent research regarding the use of small molecules for HSPC expansion.
Topics of discussion may include:
- The best cell sources for HSPCs
- Methods to measure HSPC frequencies and properties in culture
- When to purify HSPCs and how (or when not to) for culture
- How to use HSPC cultures to measure the hematotoxicity of new drug candidates
- How to exploit molecular regulators of HSPC function to drive HSPC expansion in culture
- Methods to generate large numbers of specific blood cells (e.g. erythrocytes and platelets) by promoting HSPC expansion and lineage-specific differentiation.
- The use of HSPCs and culture-expanded erythroid cells as cell sources for reprogramming to generate pluripotent stem cells
- Examples of the successful translation of methods to improve outcomes after clinical HSPC transplantation
Please take advantage of the opportunity to ask our expert a question and participate in a discussion on serum-free conditions for the ex vivo expansion of human hematopoietic stem and progenitor cells.
This session is no longer taking submissions. To be notified of new Ask the Expert sessions, join our mailing list.
What is your advice for the best way to isolate hematopoietic stem cells from cord blood and remove erythroblasts?
Hematopoietic stem and progenitor cells (HSPCs) are very rare in cord blood (and in other cell sources such as bone marrow and mobilized peripheral blood). For many applications it is important to obtain HSPC preparations that are relatively free of mature cells. EasySep™ column-free immunomagnetic cell isolation may be used to either deplete mature blood cells resulting in a sample enriched for untouched CD34+ cells, or to directly select for CD34+ cells resulting in a sample with a higher purity of HSPCs. This should effectively deplete erythroblasts as these do not express CD34, but do express mature blood cell markers, such as glycophorin-A. Alternatively, standard density gradient centrifugation may be combined with RosetteSep™ selection to enrich for lineage marker-negative (Lin-) cells by depleting mature blood cells and their immediate precursors, including erythroblasts. You can also combine negative and positive selection methods (i.e., RosetteSep™ pre-enrichment followed by EasySep™ positive selection of CD34+ cells) to achieve the highest possible CD34+ cell purity from whole cord blood. For more information, please read our technical bulletin on the isolation of CD34+ cells from human cord blood. Purified CD34+ cells can be used directly in culture, or purified further by fluorescence-activated cell sorting (FACS) to isolate subsets of CD34+ cells that are more highly enriched for hematopoietic stem cells or immature progenitor cells.
That depends on the goal of the experiment and the cell types you want to obtain. For all applications I would recommend using a serum-free medium, such as StemSpan™ SFEM or SFEM II, as these have been developed to optimally support HSPCs in culture. Dependent on the application, you will need to add different combinations of cytokines. For example, if you want to increase the number of CD34+ cells you need to supplement the medium with cytokines such as TPO, SCF and FLT3-ligand. You can add one or more other cytokines such as IL-3, IL-6, GM-CSF and/or G-CSF to increase cell yields, or use previously optimized StemSpan™ expansion supplements, such as CC100, CC110 or our new CD34+ expansion supplement for more consistent results. However, you need to be aware that it is not possible to expand HSPCs indefinitely without also inducing their differentiation. Some culture conditions can transiently preserve or even increase the number of functional HSPCs during several days or weeks of culture, but eventually the cells will differentiate into mature blood cells.
How effective are some of the new stem cell activators, such as SR-1 and UM171? Is it known how these molecules work?
Adding StemRegenin 1 (SR1) or UM171 to HSPC cultures improves the expansion of primitive hematopoietic cells, as compared to cytokine-only cultures without these small molecules. SR1 inhibits the aryl hydrocarbon receptor (AhR), which has a role in regulating HSC activity, but beyond that, little is known. For UM171 the target molecule and pathways inside the cell have not yet been identified, although we do know the mechanism is different from AhR antagonists, as there is a synergistic effect leading to higher expansion of HSCs when SR1 and UM171 are combined in culture. For more information on the combined effects of SR1, UM171 and cytokines in stimulating HSC expansion, check out our small molecules for ex vivo HSC expansion technical bulletin.
We are about to begin a media evaluation for our hematopoietic cultures. We don’t have time/resources to do a completely exhaustive study, so what would you recommend we use as our key parameters for evaluation. We have 6 media that we are looking at and then will take 2 to more extensive study.
There are many important parameters when setting up and evaluating hematopoietic cultures. First is the cell source: hematopoietic cells from bone marrow, cord blood and mobilized peripheral blood may behave differently and result in different cell yields in culture. Most likely you would want to use CD34+ cells or even subsets of this population that are more highly enriched for stem cells and primitive progenitors (e.g., CD34+CD38- cells), but there may be applications in which non-purified cells or mononuclear fractions are sufficient. The cell concentration at the start of the culture is also important. At low cell concentrations (e.g. 10ˆ4 CD34+ cells per mL of culture medium) overall cell expansion (i.e., the number of cells generated per input CD34+ cell) is generally better than at high cell concentrations and there is less chance that the medium will be depleted due to overgrowth of cells in culture. However, this is very dependent on the quality and type of cells used, and on the culture conditions, specifically the properties of the medium and the types and concentrations of cytokines used. You also need to establish clear and measurable goals about the numbers and types of cells you want to generate in your cultures and what methods are needed to characterize these cells. I would monitor the cultures closely and do cell counts (of total and viable cells) regularly. You would want to use a medium that maintains high viability (> 90%) of the cells throughout the culture. StemSpan™ SFEM II is optimized for the culture of hematopoietic cells isolated from human bone marrow, cord blood and mobilized peripheral blood, and does not contain serum or cytokines, allowing you complete flexibility in defining your culture conditions. If your goal is to expand CD34+ cells you should monitor the cultures closely for changes in the % of CD34+ cells (or CD34 subsets) by flow cytometry. If it is important that the cultured hematopoietic cells retain their progenitor or even stem abilities they will need to be tested in appropriate functional assays, such as the colony-forming unit (CFU) assay, long-term culture-initiating cell (LTC-IC) assay or transplantation assays in immunodeficient mice. For more information on these assays, please read our mini-review on Hematopoietic Stem and Progenitor Cells.
I am seeing doubling time of our HSCs at 36 hours. I would like to decrease that but think that this time is about average. Is this what I should expect or do you have suggestions on how to improve?
The doubling time of hematopoietic cells is very dependent on the cell source, culture conditions and the stage of differentiation. CD34+ cells from cord blood tend to proliferate faster than those isolated from bone marrow. True HSCs (typically <1% of the CD34+ cells) are quiescent and will have a lag period that can last 1 or 2 days before they undergo their first division, doubling every 24 hours or so after that, in optimal culture conditions. Erythroid progenitors can double even faster. It depends on your culture conditions as to whether it is possible to decrease the doubling time of your cells. You could try adding more or different cytokines, but be aware that most culture conditions that strongly promote the proliferation of HSCs will also induce their differentiation.
Retroviral or lentiviral transduction are the established methods to introduce genes into hematopoietic stem and progenitor cells (HSPCs), and are adequate for research applications. Lentiviral transduction has become the method of choice for gene therapy applications because it results in a higher percentage of successfully transduced HSPCs and is thought to be safer.
I have found some published protocols on generating iPSCs from cord blood, but I am wondering if you have a recommendation on the simplest, most effective way to do this.
For the best results, it is important to begin with the correct starting repopulation for reprogramming. Culture-expanded CD34+ cells or erythroblasts isolated from cord blood serve as attractive starting populations for reprogramming. By first isolating CD34+ cells using our cell isolation products, and then expanding CD34+ cells in StemSpan™ SFEM II medium and/or driving their differentiation to the erythroid lineage with StemSpan™ Expansion Supplements, you generate a convenient starting cell population for reprogramming. In addition to products for reprogramming CD34+ cells isolated from cord blood, we offer a comprehensive workflow for generating iPSCs from CD34+ and erythroid progenitors isolated from peripheral blood.
I saw you listed in your blog – Examples of the successful translation of methods to improve outcomes after clinical HSPC transplantation. Could you elaborate? What do you feel are the important culture conditions that translate to transplantation success?
There have been several reports of clinical trials in which ex vivo expanded cord blood (CB) cells were transplanted together with a second non-manipulated CB unit. Typically the CD34+ cells are purified first and then expanded in a serum-free medium, such StemSpan™ SFEM, supplemented with cytokines and/or other agents.
Here are four examples of published studies in which clinical benefits were observed after CB expansion was used, and a short description of the method that was used in each:
- Delaney C et al. Nature Medicine 16: 232-236, 2010 -Cultured for 16 days with recombinant Notch-ligand and cytokines
- de Lima M et al. N Engl J Med. 367:2305-15, 2010 - Co-cultured for 14 days with mesenchymal stromal cells and cytokines
- Horwitz ME et al. J Clin Invest 124:3121-8, 2014 - Cultured for 21 days with nicotinamide and cytokines
- Cutler C et al. Blood 122: 3074-81, 2013 - Stimulated for 2 hours with Prostaglandin-E2
In all studies the accelerated engraftment of neutrophils (and in certain cases, platelets) was observed. The manipulated graft contributed to hematopoiesis during first weeks or months, but long-term hematopoiesis was mostly from the non-manipulated graft. It is thus possible that the culture methods only expanded short-term repopulating cells or improved their homing ability, but it is not clear if the most primitive cells with long-term repopulating ability were expanded or maintained in these cultures. Further improvements will likely come from studies examining the importance of graft composition on engraftment (e.g., the role of T lymphocytes in either promoting or inhibiting engraftment) and from the development better conditions to maintain or expand the most primitive HSCs in culture. Some of the new small molecule regulators of HSPC function, StemRegenin 1 (SR1) and UM171, are currently being tested for their potential to improve the engraftment potential of CB engraftment, but these studies are still at an early stage.